FDA Panel Vote on Valve Disappoints Emphasys
This article was originally published in Start Up
Executive Summary
Nearly a decade into the race to arm pulmonologists with interventional tools to treat emphysema, no clear winner is emerging. Emphasys, which had led the pack in developing a bronchial valve, hit a wall at the FDA. The question is whether competitors can fill the gap.
You may also be interested in...
Are Device VCs Becoming Spineless?
Increasing concerns over the cost and efficacy of spinal procedures have chilled VC interest in spine companies, once the hot growth area in orthopedics. So, if spine is not the answer, where will VCs find investment opportunities in orthopedics, which remains one of the largest device sectors?
Rox Gets Blood Pumping in COPD
Rox Medical is taking an unusual approach to treating COPD by introducing a vascular device that increases oxygen delivery to tissue and cardiac output. The potential has investors' hearts racing as well.
Rox Gets Blood Pumping in COPD
Rox Medical is taking an unusual approach to treating COPD by introducing a vascular device that increases oxygen delivery to tissue and cardiac output. The potential has investors' hearts racing as well.